Stock Events

Stock Events

Enzon Pharmaceuticals 

$6
10
+$0.45+8.11% Friday 20:00

Statistics

Day High
0.06
Day Low
0.05
52W High
12.99
52W Low
0.05
Volume
207,734
Avg. Volume
721
Mkt Cap
445.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Oct 19
$12
Mar 19
$6
Sep 17
$15
Dec 16
$15
Dec 15
$25
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0.01
-0
0
Expected EPS
0
Actual EPS
-0.01

Financials

-1,911.54%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
52,000Revenue
-994,000Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENZN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs for infectious diseases, a market Enzon Pharmaceuticals also targets.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm focusing on novel therapeutics, including treatments for serious illnesses, overlapping with Enzon's therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, similar to Enzon's mission.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a broad range of drugs and vaccines, competing across several of the same therapeutic areas as Enzon.
Merck
MRK
Mkt Cap214.76B
Merck operates in the pharmaceutical sector, focusing on drugs for conditions that Enzon Pharmaceuticals also aims to treat, making them direct competitors.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a research-based biopharmaceutical company with a significant focus on developing treatments for serious diseases, competing with Enzon in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in the invention of medicines for serious medical conditions, directly competing with Enzon in the biopharmaceutical field.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a biotechnology company that develops therapies for neurological and neurodegenerative diseases, competing with Enzon in the biopharmaceutical market.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for creating new possibilities in medicine to cure diseases and improve people's lives, competing with Enzon in drug innovation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including areas where Enzon operates.

About

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Show more...
CEO
Mr. Richard L. Feinstein CPA
Country
US
ISIN
US2939041081

Listings

OTC Link
US
ENZND
OTCM
US
ENZN

0 Comments

Share your thoughts

FAQ

What is Enzon Pharmaceuticals stock price today?▼
The current price of ENZN is $6 USD — it has increased by +8.11% in the past 24 hours. Watch Enzon Pharmaceuticals stock price performance more closely on the chart.
What is Enzon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enzon Pharmaceuticals stocks are traded under the ticker ENZN.
Is Enzon Pharmaceuticals stock price growing?▼
ENZN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Enzon Pharmaceuticals has showed a -40% decrease.
What is Enzon Pharmaceuticals market cap?▼
Today Enzon Pharmaceuticals has the market capitalization of 445.29M
What were Enzon Pharmaceuticals earnings last quarter?▼
ENZN earnings for the last quarter are -0.01 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enzon Pharmaceuticals revenue for the last year?▼
Enzon Pharmaceuticals revenue for the last year amounts to 52,000 USD.
What is Enzon Pharmaceuticals net income for the last year?▼
ENZN net income for the last year is -994,000 USD.
Does Enzon Pharmaceuticals pay dividends?▼
Yes, ENZN dividends are paid annual. The last dividend per share was 12 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Enzon Pharmaceuticals located?▼
Enzon Pharmaceuticals operates in the Health Care sector.
When did Enzon Pharmaceuticals complete a stock split?▼
The last stock split for Enzon Pharmaceuticals was on March 25, 2026 with a ratio of 1:100.
Where is Enzon Pharmaceuticals headquartered?▼
Enzon Pharmaceuticals is headquartered in Cranford, US.